Pfizer has asked the FDA to authorize booster doses of its Covid vaccine. The company says that there is a risk of weakening or ending the immunity present inside the body after six months. The top scientist of Pfizer Inc. (PFEN) says that this has been done in view of the increasing risk of re-infection after six months and increasing cases of delta variants.
A statement issued by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said that people who have been fully vaccinated do not need a booster dose at this time. Some other scientists have also questioned the booster dosage.
The joint statement of the FDA and CDC also said that if the science is ready to explain and tell us that we need this booster dose, then we are ready for the booster dose. Pfizer's own data says that after six months, the effectiveness of the vaccine against the virus remains only 80 percent.
Mikael Dolsten, the chief scientist at Pfizer Company, says that recently revealed reports show that the effectiveness of the vaccine in Israel has proved to be low in people who took the vaccine in January and February. Most of such people were victims of infection. Israel's Health Minister says that in June the vaccine has proved to be less effective on those with infections and mild symptoms. During this, its effectiveness has been found to be 64 percent.
During an interview, Dolsten said that the vaccine developed by the company is also effective on the delta variant. But after six months, he said, "the risk of reinfection in the form of antibodies, as predicted, is likely. Although Pfizer has not made public any data from Israel. Will be published soon. Dolsten says this is a lot of data, but he believes the trend is completely correct. After six months, the delta variant can spread more quickly and take a serious form. Because of this, the infection can increase and there is a risk of developing mild symptoms.
Dolsten says he stressed that data from Israel and the UK shows that the vaccine remains effective against serious illness by about 95 percent, despite a drop in antibody levels. He also said that the third dose of the vaccine promises protection.